Introduction from CSO Frank Reynolds
PixarBio’s Biodegradable Drug Delivery System locally releasing Dopamine or Dopamine Agonists (example 1)
PixarBio’s Biodegradable Drug Delivery System locally releasing Dopamine or Dopamine Agonists (example 2)
Research on Parkinson’s disease (PD) is one of the most dynamic fields of modern neuroscience. During the decades after the discovery of dopamine in the late 1950s, the field was dominated by pharmacological and neurochemical approaches.
PD is inspiring diversified research and approaches that would have been impossible to foresee some 10 years ago. An increasing number of investigators from areas outside neuroscience, have joined the PD research community and are now contributing to the richness and diversity of this field.
“Impossible is just a big word thrown around by small men who find it easier to live in the world they’ve been given than to explore the power they have to change it. Impossible is not a fact. It’s an opinion. Impossible is not a declaration. It’s a dare. Impossible is potential. Impossible is temporary. Impossible is nothing.”
― Muhammad Ali
At PixarBio we believe Biomaterials are key to future PD interventions.
More and more new treatment options for PD will mandate sustained support and release of Dopamine and/or cells in order to overcome the bioengineering challenges that drugs and cells alone have failed to overcome during the last 50 years. In 2015, the gold standard of care for PD treatment, L-Dopa, was invented in 1968.
It is our hope that this formidable challenge will be achieved by our PixarBio team and our resources; to develop knowledge and technologies creating novel treatment options–and eventually a cure–for all who suffer from Parkinson’s disease.